Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The fibromyalgia bladder index.

Kaye Brand1, Geoffrey Littlejohn2, Linda Kristjanson3

  • 1Faculty of Communications, Health and Science, Edith Cowan University, Perth, Australia.

Clinical Rheumatology
|May 4, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Real‑World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis.

Rheumatology and therapy·2025
Same author

Neuroinflammatory and Immunological Aspects of Fibromyalgia.

Brain sciences·2025
Same author

The Relationship Between Patient-Reported Quality of Life and Physician-Derived Clinical Outcomes in Rheumatoid Arthritis in the Australian OPAL Dataset.

International journal of rheumatic diseases·2025
Same author

Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis.

Rheumatology and therapy·2025
Same author

Optimising patient outcomes: temporal trends in remission rates of rheumatoid arthritis patients in the Australian OPAL dataset between 2009 and 2022.

Clinical rheumatology·2024
Same author

Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia.

Clinical rheumatology·2024

A new Fibromyalgia Bladder Index effectively measures urinary symptoms in women with fibromyalgia syndrome (FM). This validated tool enhances understanding and management of bladder issues associated with FM.

Area of Science:

  • Urology
  • Rheumatology
  • Psychometrics

Background:

  • Fibromyalgia syndrome (FM) frequently involves sensory urinary symptoms.
  • Existing instruments like the Interstitial Cystitis Symptom and Problem Index (ICSI/ICPI) may not fully capture these symptoms in FM patients.

Purpose of the Study:

  • To validate the ICSI/ICPI for assessing urinary symptoms in women with FM.
  • To develop a specific instrument for fibromyalgia-associated bladder symptoms.

Main Methods:

  • Ninety women with FM and bladder symptoms underwent urological screening.
  • Participants completed the ICSI/ICPI, Fibromyalgia Impact Questionnaire (FIQ), and other validated scales.
  • Factor analysis was used to assess the instrument's structure and reliability.

Related Experiment Videos

Main Results:

  • Factor analysis revealed two distinct components, leading to the development of the Fibromyalgia Bladder Index.
  • The new index demonstrated high internal consistency (Cronbach's alpha = 0.81) and test-retest reliability (ICC = 0.85).
  • The Fibromyalgia Bladder Index showed high concurrent validity with the King's Health Questionnaire (KHQ) and FIQ.

Conclusions:

  • The Fibromyalgia Bladder Index is a validated, FM-specific instrument for sensory bladder symptoms.
  • This index accurately reflects bladder symptomatology and its impact in the fibromyalgia population.
  • The Fibromyalgia Bladder Index can improve the understanding and management of bladder problems in FM.